Alector, Inc. (ALEC)
2.585
-0.14
(-4.96%)
USD |
NASDAQ |
Sep 03, 12:53
Alector Enterprise Value : 163.67M for Sept. 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 02, 2026 | 163.67M |
| September 01, 2026 | 127.94M |
| August 31, 2026 | 112.30M |
| August 28, 2026 | 121.24M |
| August 27, 2026 | 126.82M |
| August 26, 2026 | 134.64M |
| August 25, 2026 | 123.47M |
| August 24, 2026 | 116.77M |
| August 21, 2026 | 123.47M |
| August 20, 2026 | 112.30M |
| August 19, 2026 | 131.29M |
| August 18, 2026 | 106.72M |
| August 17, 2026 | 88.86M |
| August 14, 2026 | 78.81M |
| August 13, 2026 | 87.74M |
| August 12, 2026 | 100.02M |
| August 11, 2026 | 93.32M |
| August 10, 2026 | 48.66M |
| August 07, 2026 | 58.71M |
| August 06, 2026 | 64.29M |
| August 05, 2026 | 26.33M |
| August 04, 2026 | 31.91M |
| August 03, 2026 | 28.56M |
| July 31, 2026 | 28.56M |
| July 30, 2026 | 40.84M |
| Date | Value |
|---|---|
| July 29, 2026 | 29.68M |
| July 28, 2026 | 29.68M |
| July 27, 2026 | 28.56M |
| July 24, 2026 | 25.21M |
| July 23, 2026 | 26.33M |
| July 22, 2026 | 30.79M |
| July 21, 2026 | 31.91M |
| July 20, 2026 | 19.63M |
| July 17, 2026 | 27.45M |
| July 16, 2026 | 24.10M |
| July 15, 2026 | 27.45M |
| July 14, 2026 | 15.16M |
| July 13, 2026 | 28.56M |
| July 10, 2026 | 39.73M |
| July 09, 2026 | 42.52M |
| July 08, 2026 | 64.29M |
| July 07, 2026 | 75.46M |
| July 06, 2026 | 76.57M |
| July 02, 2026 | 89.97M |
| July 01, 2026 | 84.39M |
| June 30, 2026 | 84.39M |
| June 29, 2026 | 58.97M |
| June 26, 2026 | 34.54M |
| June 25, 2026 | 33.43M |
| June 24, 2026 | 26.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.82B |
| Oncolytics Biotech, Inc. | 106.01M |
| Sangamo Therapeutics, Inc. | 62.59M |
| Sarepta Therapeutics, Inc. | 2.709B |
| Anixa Biosciences, Inc. | 91.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.99M |
| Revenue (Quarterly) | 3.32M |
| Total Expenses (Quarterly) | 26.31M |
| EPS Diluted (Quarterly) | -0.2067 |
| Gross Profit Margin (Quarterly) | 38.28% |
| Profit Margin (Quarterly) | -692.5% |
| Earnings Yield | -42.25% |
| Normalized Earnings Yield | -40.35 |